LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Eric Linsley offers perspective on personalized medicine’s development
News | 03. 06. 2012
Eric Linsley offered his perspective on personalized medicine’s development during a symposium for PMC's recent report, The Case for Personalized Medicine. Linsley joined Jennie Hunter-Cevera, Ph.D., Executive Vice President, RTI International; Jonathan Roy, Senior Director and Head of Commercial Diagnostics for GlaxoSmithKline; Amy Abernethy, M.D., Director, Cancer Care Research Program at Duke University and David King, CEO of the Laboratory Corporation of America.
The Personalized Medicine Coalition latest newsletter summarizes these perspectives.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.